AZN AstraZeneca PLC Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
03:24
Sep 12
seedy19tron
Bearish call on SERD/CERAN drug class
Speaker asserts the SERD/CERAN drug class has "overstayed its welcome," a bearish mention of AstraZeneca and Olema, but provides no catalyst or mechanism.
AZN AstraZeneca PLC Avoid — —
03:23
Sep 09
FirstSquawk
RBC initiates coverage on AstraZeneca with an outperform rating and a price target of 14,500. News
RBC initiates coverage on AstraZeneca with an outperform rating and a price target of 14,500 pence per share.
AZN AstraZeneca PLC Long 1ST — —
00:00
Sep 09
Jim Cramer CNBC
CNBC
AstraZeneca trial misses, avoid
Cramer is nervous about AstraZeneca because it has been missing some trials. He does not think the COPD opportunity is enough to change his mind and would not put his money on the stock.
AZN AstraZeneca PLC Avoid — —
Log in to see ideas

About AZN Investor Commentary

Across the available history and selected sources, Buzzberg tracks AZN (AstraZeneca PLC) across 16 sources: 15 bullish vs 0 bearish calls from 38 authors. Historical directional balance: 12% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 121 total trade ideas tracked. Past 7 days, before deduplication: 3 other directions. Latest voices: seedy19tron, FirstSquawk, Jim Cramer.